# Ovation Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ovation-life-sciences

- Industry: Software
- Headquarters: Cambridge, US
- Website: www.ovation.io
- Total disclosed funding: $28M
- Latest round: Series B (Dec 16, 2020)
- Investors on record: 6

## About

Ovation Life Sciences, LLC is a biotechnology firm focused on generating high-value genomic and omics data linked to longitudinal clinical data, enhancing drug discovery across therapeutic areas.Founded in 2009 in Cambridge, US, Ovation Life Sciences specializes in genomic and omics data linked to clinical data. The company has undergone significant developments, including a merger with PD Theranostics, Inc. in August 2024, enhancing its data offerings. The founding team includes Barry Wark, Jason Painter, and Winston Brasor, while Barry Wark serves as CEO. Ovation has completed a total of 8 deals, with the most recent being a Series B funding round in which they raised USD 21.50 mn, led by SignalFire and supported by investors including Black Point Group, Borealis Ventures, Madrona Venture Group, and StageDotO.Ovation.io specializes in generating high-value genomic and omics data intricately linked to extensive longitudinal clinical data. Key products include the Ovation Research Network, which mobilizes remnant samples for human health research, and Ovation LIMS, a laboratory information management system for molecular diagnostic laboratories. Their datasets, particularly on inflammatory bowel disease, offer comprehensive multiomics data, including whole genome and RNA sequencing, paired with curated clinical information to enhance biomarker discovery and patient stratification. The firm serves the life sciences and clinical laboratory markets, catering to research institutions and pharmaceutical companies across North America and Europe.Ovation.io generates revenue through subscription models and partnerships within the life sciences sector. Clients access proprietary datasets and laboratory management solutions via annual contracts or project-based agreements. For example, subscriptions to the Ovation Research Network allow clients to utilize specific multiomics datasets for tailored research. This transactional model fosters direct relationships with laboratories and institutions, alongside collaborations with pharmaceutical companies, enhancing revenue through specialized data products essential for advancing precision medicine initiatives.In August 2024, Ovation Life Sciences, LLC merged with PD Theranostics, Inc. to form Ovation Life Sciences, LLC/PD Theranostics, Inc., a move aimed at producing a comprehensive database of linked omics and clinical data for various diseases. The merger is expected to enhance their capabilities in data integration and research support. Future plans include the development of new products and expansion into additional geographic markets, though specific details on upcoming product launches or targeted regions have not been disclosed. The recent Series B funding round of USD 21.50 mn will support these growth initiatives, further advancing their mission in the life sciences sector.

## Funding rounds

- Series B, Dec 16, 2020, $22M — Madrona Venture Group, Borealis Ventures, Black Point Group, SignalFire, Stage
- Series A, Mar 14, 2019, $5M — Madrona Venture Group, Borealis Ventures, Stage
- Seed, Jan 8, 2018, $1.9M — Longfellow Venture Partners, Stage

## Investors

- Longfellow Venture Partners — Seed
- Stage (https://capitalatlas.ai/funds/stage) — Seed, Series A, Series B
- Madrona Venture Group (https://capitalatlas.ai/funds/madrona-venture-group) — Series A, Series B
- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Series A, Series B
- Black Point Group (https://capitalatlas.ai/funds/black-point-group) — Series B
- SignalFire (https://capitalatlas.ai/funds/signalfire) — Series B